Forbes -- European Union regulators expanded the approval of Merck and Co.'s HIV drug Isentress, the company said Tuesday. Merck said the drug is now approved for adult patients who are starting treatment for the first time. Previously it was only approved for patients who had not been helped by other drugs. The ruling was made by the European Union Commission and announced by the company’s Merck Sharp & Dohme unit.
